Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
ID: 358086Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358086

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAS-25-073.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Jan 8, 2025, 12:00 AM UTC
  4. 4
    Due Jan 7, 2028, 12:00 AM UTC
Description

The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "Priority HIV/AIDS Research" under the R01 grant mechanism. This initiative aims to stimulate research that aligns with NIH’s priorities regarding HIV/AIDS, particularly focusing on systemic complications such as metabolic, gastrointestinal, and kidney issues arising from HIV, while encouraging the incorporation of health-impeding social determinants of health into research proposals. The anticipated funding amount is $2 million, with plans to support 3 to 5 awards over five years, and applications are due starting May 7, 2025. Interested applicants can find more information and application guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
PAS-25-073-Full-Announcement.html
Jan 10, 2025, 12:05 PM UTC
PAS-25-073.html
Jan 10, 2025, 12:05 PM UTC
The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is announcing a funding opportunity titled "Priority HIV/AIDS Research" under the R01 grant mechanism. This initiative aims to stimulate research that aligns with NIH’s priorities regarding HIV/AIDS, particularly focusing on systemic complications such as metabolic, gastrointestinal, and kidney issues arising from HIV. The anticipated funding amount is $2 million, with an expectation to support 3 to 5 awards over five years. Applications are due on various specific dates starting from May 7, 2025, with eligibility open to a wide range of organizations, including higher education institutions and nonprofits. Investigators are encouraged to incorporate health-impeding social determinants of health into their research proposals, highlighting their role in HIV-related comorbidities. The streamline submission process includes application preparation through Grants.gov or the NIH ASSIST system, with strict adherence to application guidelines emphasized. Successful proposals will undergo a rigorous peer review, assessing the research significance, innovation, rigor, and potential impact. This funding opportunity highlights NIH’s commitment to advancing understanding of the intersection between HIV and related health conditions, promoting comprehensive research to improve public health outcomes.
Similar Opportunities
Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is inviting applications for the grant opportunity titled "Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK." This funding initiative aims to support innovative pilot research projects that explore the biological, behavioral, and social mechanisms related to HIV pathogenesis, particularly focusing on comorbidities and complications affecting organs and tissues relevant to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The research is expected to enhance understanding of the interplay between HIV and associated health issues, with a funding cap of $275,000 over two years for successful applications. Interested applicants, including higher education institutions and various nonprofit organizations, should note that the application deadlines begin in April 2025, with the final submission date set for January 7, 2028. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)" aimed at stimulating research related to HIV/AIDS within the National Institute on Deafness and Other Communication Disorders (NIDCD). This initiative encourages applications that address high-priority research areas identified by the NIH Office of AIDS Research, particularly focusing on the intersections of HIV/AIDS with hearing, communication, and associated disorders. Grants of up to $499,999 in direct costs are available for projects lasting up to five years, with no cost-sharing or matching requirements. Interested applicants, including educational institutions and community organizations, must adhere to NIH guidelines and submit their proposals through Grants.gov by the closing date of January 7, 2028. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)." This initiative aims to support multilevel and multidisciplinary intervention research focused on improving the quality of life and promoting successful aging among individuals living with HIV, particularly those from racial and ethnic minority groups and lower socioeconomic backgrounds. The funding, which ranges from $5-6 million to support approximately 5-6 awards, will provide a maximum budget of $750,000 annually over five years for projects that address social determinants of health and involve community engagement. Interested applicants can find more details and guidelines on the NIH website, with the application process opening on November 11, 2023, and a submission deadline of December 12, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD," aimed at stimulating research related to HIV/AIDS and communication disorders. This initiative encourages applications that address high-priority research areas defined by the NIH Office of AIDS Research, focusing on the impact of HIV on hearing, balance, taste, smell, voice, speech, and language, with a budget limit of $275,000 for a two-year project period. Eligible applicants include a diverse range of institutions and organizations, and only low-risk clinical trials that do not require FDA oversight will be supported. Interested parties can find more information and application details at the NIH grants website, with deadlines for submissions ranging from May 2025 to January 2028.
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)" aimed at stimulating research related to communication disorders associated with HIV/AIDS. This initiative encourages innovative, hypothesis-driven research that addresses high-priority areas such as hearing, speech, and language, with a focus on low-risk clinical trials that do not require FDA oversight. Eligible applicants include a wide range of organizations, such as higher education institutions and community-based organizations, with funding available up to $499,999 per year for projects lasting up to five years. Interested parties should submit their applications by January 7, 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the announcement page at https://grants.nih.gov/grants/guide/pa-files/PAR-23-099.html.
High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities (R01 - Clinical Trials Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities." This initiative aims to support research that investigates the underlying mechanisms contributing to health disparities in HIV and aging, particularly focusing on how multiple comorbidities affect health outcomes and quality of life among individuals from marginalized populations. The program emphasizes a multidisciplinary approach and encourages engagement with community stakeholders to enhance the relevance of the research. Approximately $3 million is available for four awards and $1.5 million for two additional awards for fiscal year 2024, with a project duration of up to five years. Interested applicants can find more information and guidelines at the NIH Grants website and should direct inquiries to grantsinfo@nih.gov. The application deadline is set for January 7, 2026.